Transglutaminase 2: Biology, Relevance to Neurodegenerative Diseases and Therapeutic Implications
Introduction
Transglutaminases (TGs) are enzymes that catalyze the formation of isopeptide bonds – a type of covalent linkage between two protein molecules. To date, nine members of the TG family have been identified, of which transglutaminase 2 (TG2) is highly expressed in the human central nervous system (CNS) (Beninati and Piacentini, 2004, Ruan and Johnson, 2007, Siegel and Khosla, 2007). TG2 is unique among this family of proteins in that it has multiple additional enzymatic activities (Martin et al., 2006, Siegel and Khosla, 2007). More importantly, TG2 has been implicated in multiple disease states, including celiac disease and several degenerative disorders of the brain (Martin, et al., 2006).
Neurodegenerative disorders encompass a number of chronic progressive diseases that are characterized by the loss of select neuronal populations in the CNS, which underlie their respective clinical phenotypes, and the aggregation of disease-specific pathogenic proteins in hallmark lesions that highlight the neuropathology of each disorder. The common theme of abnormal protein aggregates and the accumulating evidence that certain forms of these aggregates can be neurotoxic have provided the rationale to develop various approaches to inhibit or clear protein aggregates as potential neuroprotective therapeutic strategies. Factors that promote the formation of these aggregates have also been the subject of intense investigations with the objective of identifying interventions that can slow the progressive disease process. One of these factors is the cross-linking of pathogenic proteins into toxic higher order oligomers by the enzymatic activity of TG2. Other commonalities among these disorders include loss of calcium homeostasis, energy depletion, and increased generation of reactive oxygen species in affected cells, all of which may contribute to the activation of TG2. In this review, we discuss the biochemistry of TG2 and its pathogenic role in neurodegenerative disorders. We also describe efforts towards developing inhibitors of TG2 that could be used as disease modifying therapies for these as yet incurable conditions.
Section snippets
Enzymatic functions of TG2
TG2 is highly versatile functionally with multiple domains (Fig. 1). In addition to being a transamidating enzyme, it has activities as a GTPase, a protein disulfide isomerase, a protein kinase, and an isopeptidase (Chen and Mehta, 1999, Fesus and Piacentini, 2002, Hasegawa et al., 2003, Mishra and Murphy, 2004, Martin et al., 2006, Siegel and Khosla, 2007, Iismaa et al., 2009). These various functions are important in its physiological roles and may each contribute to disease states.
Structural/functional correlates
The gene coding for TG2 is on chromosome 20(q11-12) in humans (Gentile et al., 1994, Chen and Mehta, 1999, Lesort et al., 2000, Martin et al., 2006, Iismaa et al., 2009). It contains 13 exons and 12 introns (Gentile et al., 1991, Fraij and Gonzales, 1997, Chen and Mehta, 1999, Lesort et al., 2000) and is 32.5 kilobases long (Fraij and Gonzales, 1997, Lesort et al., 2000). TGs are found in a wide range of species from bacteria to humans, with the catalytic triad necessary for cross-linking
The impact of TG2 localization on its functions
Of the known TGs, TG2 is the most ubiquitous (Lesort, et al., 2000). It is found in many neural tissues including the brain, spinal cord, and peripheral nerves (Gilad and Varon, 1985, Johnson et al., 1997, Lesort et al., 2000). Within the brain, it is present in many regions including frontal and temporal cortex, hippocampus, substantia nigra and cerebellum (Appelt et al., 1996, Johnson et al., 1997, Kim et al., 1999, Lesort et al., 1999, Lesort et al., 2000, Andringa et al., 2004, Wilhelmus et
Physiologic roles of TG2
As might be expected from the many functions and ubiquitous nature of TG2, diverse physiological roles have been attributed to this protein. Frequently, the stable cross-links formed by TG2 serve a structural purpose, but this transglutaminase activity can also alter the function of substrate molecules (Chen & Mehta, 1999). Additionally, many of the proposed roles of TG2 are independent of its transamidation activity (Siegel & Khosla, 2007).
Regulation of TG2 expression
As might be expected of a protein such as TG2 that is widely expressed and has multiple functions, it is highly regulated at many levels (Chen & Mehta, 1999). A number of regulators increase TG2 expression, many of which vary based on cell type (Chen and Mehta, 1999, Lesort et al., 2000), although some generalizations can be made. One important aspect of TG2 regulation is the frequent involvement of inflammatory mediators. For example TGF-β can both be activated by TG2 (Nunes, et al., 1997),
Mouse models with genetically manipulated TG2
TG2 is implicated in a number of diseases including many neurodegenerative disorders. As a result, genetically altered mice that either have the TG2 gene deleted or are transgenic for TG2 have been generated in order to further study this protein in vivo. Since TG2 is the predominant TG in the mouse forebrain, these studies are expected to be informative about the function of this protein in the brain (Ruan & Johnson, 2007). First, TG2 knock out mice (TG2−/−) were generated independently by two
TG2 in neurodegenerative diseases
TG2 is implicated in a number of neurodegenerative disorders including Huntington's (HD), Alzheimer's (AD), and Parkinson's diseases (PD) (Jeitner et al., 2009b) based on several lines of evidence. First, it is found throughout most brain regions, particularly in neurons (Appelt et al., 1996, Kim et al., 1999, Lesort et al., 1999), and accounts for the majority of transglutaminase activity in the mouse brain (Bailey et al., 2004). Second, the pathophysiology of all these diseases includes the
TG2 and non-neurodegenerative conditions
Although this review focuses on neurodegenerative diseases, we briefly discuss here other disorders in which TG2 is believed to be a contributing factor for two reasons: first, understanding the mechanisms through which TG2 plays a role in non-neurologic diseases can help in designing TG2 inhibitors, and second, future therapeutics aimed at inhibiting TG2 for CNS diseases may have an impact on disease processes in other parts of the body as well.
The disorder in which the role of TG2 is best
TG2 inhibitors
As a result of the putative role of TG2 in a number of disease states, there is considerable interest in developing inhibitors of this enzyme as a disease modifying therapy for these disorders. Of those currently available, cystamine is the most commonly used experimentally to inhibit TG2 activity and has long been known to have this property (Lorand & Conrad, 1984). Cystamine is the disulfide of the aminothiol cysteamine, which has the structure HS-CH2-CH2-NH2 (Thoene et al., 1976) (Lorand &
Conclusions
In conclusion, TG2 is a multifunctional enzyme that has diverse roles throughout the body. A large body of evidence has accumulated supporting the notion that TG2 plays a role in many neurodegenerative disorders, particularly HD, AD, PD, PSP and DLB although further investigations are needed to elucidate the precise role that this enzyme plays in these diseases. However, available evidence indicates that it is the cross-linking function of TG2 that leads to its pathologic activity and,
Conflict of interest
None.
Acknowledgments
M.M.M. is the William Dow Lovett Professor of Neurology and is supported by NIH grants NS059869, NS053517 and NS073994.
References (277)
- et al.
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
Neuron
(2000) - et al.
Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity
J Biol Chem
(1987) - et al.
Rapid and transient alterations in transglutaminase activity in rat superior cervical ganglia following denervation or axotomy
Neurosci Res
(1993) - et al.
Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis
J Biol Chem
(2001) - et al.
The association of tissue transglutaminase with human recombinant tau results in the formation of insoluble filamentous structures
Brain Res
(1997) - et al.
Tetanus toxin inhibits neuroexocytosis even when its Zn(2+)-dependent protease activity is removed
J Biol Chem
(1995) - et al.
Phospholipase Cdelta1 is a guanine nucleotide exchanging factor for transglutaminase II (Galpha h) and promotes alpha 1B-adrenoreceptor-mediated GTP binding and intracellular calcium release
J Biol Chem
(2001) - et al.
Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases
Mol Cell Neurosci
(2004) - et al.
The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase
Neurobiol Aging
(2006) - et al.
The role of tissue transglutaminase in 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in differentiated human SH-SY5Y neuroblastoma cells
Neurosci Lett
(2006)
Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity
J Biol Chem
GTP modulates calcium binding and cation-induced conformational changes in erythrocyte transglutaminase
FEBS Lett
Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb
J Biol Chem
Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease
Neurobiol Dis
Development of a mechanism-based assay for tissue transglutaminase–results of a high-throughput screen and discovery of inhibitors
Anal Biochem
Mitochondria, calcium and cell death: a deadly triad in neurodegeneration
Biochim Biophys Acta
Tissue transglutaminase: an enzyme with a split personality
Int J Biochem Cell Biol
Alpha1-adrenergic receptor signaling via Gh is subtype specific and independent of its transglutaminase activity
J Biol Chem
Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2
Chem Biol
Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease
J Biol Chem
Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration
Neurochem Int
Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases?
Neurochem Int
Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration
Cell
Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid
Am J Pathol
The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates
Biochem Biophys Res Commun
Synthesis of dipeptide-bound epoxides and alpha, beta-unsaturated amides as potential irreversible transglutaminase inhibitors
Bioorg Med Chem
Structure-activity relationship study of novel tissue transglutaminase inhibitors
Bioorg Med Chem Lett
Covalent modification of synapsin I by a tetanus toxin-activated transglutaminase
J Biol Chem
Extracellular transglutaminase 2 activates beta-catenin signaling in calcifying vascular smooth muscle cells
FEBS Lett
Evidence that phospholipase delta1 is the effector in the Gh (transglutaminase II)-mediated signaling
J Biol Chem
Transglutaminase 2: an enigmatic enzyme with diverse functions
Trends Biochem Sci
Transglutaminase 2 in the balance of cell death and survival
FEBS Lett
Induction and activation of tissue transglutaminase during programmed cell death
FEBS Lett
Transglutaminase 2 protects against ischemic stroke
Neurobiol Dis
The epsilon-(gamma-glutamyl)lysine crosslink and the catalytic role of transglutaminases
Adv Protein Chem
Organization and structure of the human tissue transglutaminase gene
Biochim Biophys Acta
Protein cross-linking by transglutaminase induced in long-term potentiation in the Ca1 region of hippocampal slices
Neuroscience
Propagation of tau misfolding from the outside to the inside of a cell
J Biol Chem
Tissue transglutaminase is an important player at the surface of human endothelial cells: evidence for its externalization and its colocalization with the beta(1) integrin
Exp Cell Res
The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization
Genomics
tTGase/G alpha h protein expression inhibits adenylate cyclase activity in Balb-C 3T3 fibroblasts membranes
Biochim Biophys Acta
Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases
J Biol Chem
Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases
Arch Biochem Biophys
Regulation of transglutaminase type II by transforming growth factor-beta 1 in normal and transformed human epidermal keratinocytes
J Biol Chem
Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor
Prog Neuropsychopharmacol Biol Psychiatry
The propagation of prion-like protein inclusions in neurodegenerative diseases
Trends Neurosci
Three different human tau isoforms and rat neurofilament light, middle and heavy chain proteins are cellular substrates for transglutaminase
Neurosci Lett
Synthesis and evaluation of peptidic maleimides as transglutaminase inhibitors
Bioorg Med Chem Lett
Transglutaminase-catalyzed matrix cross-linking in differentiating cartilage: identification of osteonectin as a major glutaminyl substrate
J Cell Biol
Transglutaminases: protein cross-linking enzymes in tissues and body fluids
Thromb Haemost
Cited by (49)
Cooperation of cell adhesion and autophagy in the brain: Functional roles in development and neurodegenerative disease
2021, Matrix Biology PlusCitation Excerpt :Additionally, transglutaminase activity is increased in patient brains associated with these diseases. These findings, combined with the TG2 function as an autophagic inhibitor [219], suggest that aberrant TG2 activity may be at least one of the mechanisms reducing autophagy in these diseases to contribute to pathogenesis – cross-linking aggregation-prone versions of disease-causing proteins and reducing autophagic mechanisms that would aid in aggregate clearance, further tipping protein homeostasis and autophagic balance in a pathogenic direction. Additionally, the disease-causing proteins themselves may contribute to aberrant TG2-mediated autophagy.
Inflammatory mediators resulting from transglutaminase 2 expressed in mast cells contribute to the development of Parkinson's disease in a mouse model
2018, Toxicology and Applied PharmacologyReaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors
2018, Journal of Molecular Graphics and ModellingTransglutaminase 2 modulation of NF-κB signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury
2017, Brain ResearchCitation Excerpt :TG2 belongs to a class of enzymes known as the transglutaminases. TG2 is unique in this class of proteins, as it is ubiquitously expressed in all cell types within the brain, and can be found in most subcellular compartments (Espitia Pinzon et al., 2014; Grosso and Mouradian, 2012; Hilton et al., 1997; Hwang et al., 2009; Kim et al., 1999; Lesort et al., 1998, 1999; Lorand and Graham, 2003; Mastroberardino et al., 2006; Piacentini et al., 2002, 2014; van Strien et al., 2011a,b). The most commonly studied function of TG2 is its role as a transamidation enzyme, which typically involves the catalysis of the formation of an isopeptide linkage between the γ-carboxamide group of a glutamine residue and the ε-amino group of a lysine residue (Gundemir et al., 2012).